What is the role of cobicistat (Tybost) in antiretroviral therapy for HIV infection in adolescents and young adults?

1. U.S. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 2018 May 30. [Full Text].

2. Kahana SY, Rohan J, Allison S, Frazier TW, Drotar D. A meta-analysis of adherence to antiretroviral therapy and virologic responses in HIV-infected children, adolescents, and young adults. AIDS Behav. 2013 Jan. 17(1):41-60. [Medline].

3. Pharmacokinetics and pharmacodynamics in adolescents. January 20-21, 1994. Proceedings. J Adolesc Health. 1994 Dec. 15(8):605-78. [Medline].

4. El-Sadar W, Oleske JM, Agins BD, et al. Evaluation and management of early HIV infection. Clinical Practice Guideline No. 7 (AHCPR Publication No. 94-0572). Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services, 1994.

5. [Guideline] Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. AIDSInfo. Available at https://aidsinfo.nih.gov/guidelines/html/2/pediatric-arv/0. 4/16/19; Accessed: 5/29/19.

6. U.S. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. 2017 Apr 27. [Full Text].

7. Viani RM, Peralta L, Aldrovandi G, et al. Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study. J Infect Dis. 2006 Dec 1. 194(11):1505-9. [Medline].

8. Biktarvy (bictegravir/emtricitabine/tenofovir AF) [package insert]. Foster City, CA: Gilead Sciences, Inc. June 2019. Available at [Full Text].

9. Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) [package insert]. Titusville NJ: Janssen Therapeutics, Division of Janssen Products. March 2020. Available at [Full Text].

10. Takuva S, Evans D, Zuma K, Okello V, Louwagie G. Comparative durability of nevirapine versus efavirenz in first-line regimens during the first year of initiating antiretroviral therapy among Swaziland HIV-infected adults. Pan Afr Med J. 2013. 15:5. [Medline]. [Full Text].

11. Loutfy MR, Walmsley SL, Klein MB, Raboud J, Tseng AL, Blitz SL, et al. Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study. BMC Infect Dis. 2013 Jun 3. 13:256. [Medline]. [Full Text].

12. Isentress HD (raltegravir) [package insert]. Whitehouse Station, NJ: Merck & Co, Inc. 2017 May. Available at [Full Text].

David J Cennimo, MD, FAAP, FACP, AAHIVS Assistant Professor of Medicine and Pediatrics, Adult and Pediatric Infectious Diseases, Rutgers New Jersey Medical School

David J Cennimo, MD, FAAP, FACP, AAHIVS is a member of the following medical societies: American Academy of HIV Medicine, American Academy of Pediatrics, American College of Physicians, American Medical Association, HIV Medicine Association, Infectious Diseases Society of America, Medical Society of New Jersey, Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Michelle R Salvaggio, MD, FACP Assistant Professor, Department of Internal Medicine, Section of Infectious Diseases, University of Oklahoma College of Medicine; Medical Director of Infectious Diseases Institute, Director, Clinical Trials Unit, Director, Ryan White Programs, Department of Medicine, University of Oklahoma Health Sciences Center; Attending Physician, Infectious Diseases Consultation Service, Infectious Diseases Institute, OU Medical Center

Michelle R Salvaggio, MD, FACP is a member of the following medical societies: American College of Physicians, Infectious Diseases Society of America

Disclosure: Received honoraria from Merck for speaking and teaching.